Kidney stone biology: insights from genetics

Kidney stone disease (KSD) affects >10% of the global population and has a high likelihood of recurrence. Its prevalence has risen significantly in recent decades, posing a substantial economic burden. Moreover, KSD is linked to several comorbidities, amplifying its impact on general health and well-being. Environmental factors play a critical role in KSD development, acting upon an underlying genetic substratum. These genetic factors affect the regulation of stone-forming elements and natural inhibitors of crystallization within the kidney. Understanding the interplay between genetic and environmental factors is essential for improving KSD management. Tailored dietary interventions and targeted therapies can address individual risk profiles, reducing the burden of this complex disease. We believe that the common form of KSD, which is the one observed in the general population, is indeed a heterogeneous condition characterized by significant variability in the influence of environmental and genetic factors among patients as well as distinct biological pathways involved in lithogenesis for each individual. The aim of this review is to describe the relevant biology of nephrolithiasis, leveraging 'experiments of nature', specifically the known genetic associations of KSD and the resulting biological and physiological derangements. We hypothesize that the carriers, molecular pathways and physiological processes identified in this manner play a major role in the biology of lithogenesis, not only in rare genetic nephrolithiasis, but also in 'common' KSD.

Authors

Institutions

Publication Details

Journal
Nephrology Dialysis Transplantation
Published
2025-05-14
DOI
https://doi.org/10.1093/ndt/gfaf062
Citations
4
Primary Topic
Kidney Stones and Urolithiasis Treatments
Type
article
Field-Weighted Citation Impact
6.07

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Kidney stone biology: insights from genetics

Robert J. Unwin, Giovanni Gambaro, Andrea Spasiano, Pietro Manuel Ferraro et al.
4 citations
Nephrology Dialysis Transplantation
Kidney Stones and Urolithiasis Treatments
6.07
article

Kidney stone biology: insights from genetics

Robert J. Unwin, Giovanni Gambaro, Andrea Spasiano, Pietro Manuel Ferraro, Emmanuel Letavernier
article en
4 citations

Abstract

Kidney stone disease (KSD) affects >10% of the global population and has a high likelihood of recurrence. Its prevalence has risen significantly in recent decades, posing a substantial economic burden. Moreover, KSD is linked to several comorbidities, amplifying its impact on general health and well-being. Environmental factors play a critical role in KSD development, acting upon an underlying genetic substratum. These genetic factors affect the regulation of stone-forming elements and natural inhibitors of crystallization within the kidney. Understanding the interplay between genetic and environmental factors is essential for improving KSD management. Tailored dietary interventions and targeted therapies can address individual risk profiles, reducing the burden of this complex disease. We believe that the common form of KSD, which is the one observed in the general population, is indeed a heterogeneous condition characterized by significant variability in the influence of environmental and genetic factors among patients as well as distinct biological pathways involved in lithogenesis for each individual. The aim of this review is to describe the relevant biology of nephrolithiasis, leveraging 'experiments of nature', specifically the known genetic associations of KSD and the resulting biological and physiological derangements. We hypothesize that the carriers, molecular pathways and physiological processes identified in this manner play a major role in the biology of lithogenesis, not only in rare genetic nephrolithiasis, but also in 'common' KSD.

Nephrology Dialysis TransplantationVol. 40(12)
AstraZeneca (United Kingdom) (GB), University of Verona (IT), Inserm (FR), Sorbonne Université (FR), AstraZeneca (South Korea) (KR), Azienda Ospedaliera Universitaria Integrata Verona (IT), Assistance Publique – Hôpitaux de Paris (FR), AstraZeneca (Brazil) (BR), AstraZeneca (Finland) (FI), Hôpital Tenon (FR), Maladies rénales fréquentes et rares : des mécanismes moléculaires à la médecine personnalisée
European Commission
Openalex Percentile: Top 4%
Kidney Stones and Urolithiasis Treatments
6.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.